SiBone (SIBN) to Release Earnings on Monday

SiBone (NASDAQ:SIBN) is projected to post its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect SiBone to post earnings of ($0.13) per share and revenue of $56.2610 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 23, 2026 at 4:30 PM ET.

SiBone Price Performance

Shares of NASDAQ:SIBN opened at $15.33 on Monday. The firm has a market cap of $665.17 million, a price-to-earnings ratio of -30.06 and a beta of 0.69. SiBone has a 1 year low of $12.49 and a 1 year high of $21.89. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. The business has a fifty day simple moving average of $18.18 and a 200 day simple moving average of $16.89.

Wall Street Analysts Forecast Growth

SIBN has been the subject of a number of recent research reports. Needham & Company LLC raised their price target on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. TD Cowen upgraded SiBone to a “strong-buy” rating in a report on Tuesday, January 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Truist Financial boosted their target price on shares of SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Canaccord Genuity Group raised their price target on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SiBone currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.33.

Insider Activity at SiBone

In other news, insider Anthony J. Recupero sold 3,677 shares of SiBone stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $19.62, for a total value of $72,142.74. Following the transaction, the insider owned 264,467 shares of the company’s stock, valued at $5,188,842.54. This trade represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey W. Dunn sold 20,000 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $21.28, for a total transaction of $425,600.00. Following the completion of the sale, the director owned 80,115 shares of the company’s stock, valued at $1,704,847.20. The trade was a 19.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 97,956 shares of company stock valued at $1,958,807. 3.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SIBN. Caitong International Asset Management Co. Ltd boosted its holdings in SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares during the period. State of Wyoming acquired a new position in shares of SiBone during the 2nd quarter worth about $55,000. Canada Pension Plan Investment Board acquired a new position in shares of SiBone during the 2nd quarter worth about $68,000. PNC Financial Services Group Inc. boosted its stake in SiBone by 1,443.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,305 shares of the company’s stock valued at $85,000 after purchasing an additional 4,026 shares during the period. Finally, Quarry LP grew its holdings in SiBone by 862.6% in the 3rd quarter. Quarry LP now owns 4,861 shares of the company’s stock valued at $72,000 after buying an additional 4,356 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.